{"id":1372,"date":"2026-03-28T15:00:00","date_gmt":"2026-03-28T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1372"},"modified":"2026-09-08T21:28:14","modified_gmt":"2026-09-08T21:28:14","slug":"enclomiphene-citrate-serm-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/","title":{"rendered":"Enclomiphene Citrate Research: SERM Mechanism, Testosterone Studies &#038; Hormonal Effects"},"content":{"rendered":"<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<div class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class=\"ez-toc-list ez-toc-list-level-1\"><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#What_Is_Enclomiphene\">What Is Enclomiphene?<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Chemical_Identity_and_Classification\">Chemical Identity and Classification<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#From_Clomiphene_to_Enclomiphene_The_Development_Story\">From Clomiphene to Enclomiphene: The Development Story<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Mechanism_of_Action_How_Enclomiphene_Activates_the_HPG_Axis\">Mechanism of Action: How Enclomiphene Activates the HPG Axis<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Enclomiphene_vs_Zuclomiphene_Night_and_Day\">Enclomiphene vs. Zuclomiphene: Night and Day<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Research_Findings\">Research Findings<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Enclomiphene_vs_Racemic_Clomiphene_Practical_Research_Considerations\">Enclomiphene vs. Racemic Clomiphene: Practical Research Considerations<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Where_Enclomiphene_Fits_Among_SERMs\">Where Enclomiphene Fits Among SERMs<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Safety_Profile_and_Research_Considerations\">Safety Profile and Research Considerations<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Regulatory_Status\">Regulatory Status<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Research_Compound_Availability\">Research Compound Availability<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#Conclusion\">Conclusion<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lotilabs.com\/resources\/enclomiphene-citrate-serm-research-guide\/#References\">References<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Enclomiphene\"><\/span><span class=\"ez-toc-section\" id=\"What_Is_Enclomiphene\"><\/span>What Is Enclomiphene?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Clomiphene has been around since the 1960s. One of the oldest SERMs in the book. But here\u2019s the thing most people don\u2019t realize: it\u2019s actually two drugs duct-taped together. The racemic mixture contains a trans-isomer (enclomiphene) that blocks estrogen receptors and a cis-isomer (zuclomiphene) that activates them. One foot on the gas, one on the brake. For decades, researchers just lived with that contradiction.<\/p>\n<p><a href=\"https:\/\/lotilabs.com\/product\/enclomiphene-25mg-ml\/\">Enclomiphene<\/a> is what you get when you strip the racemic mixture down to just the trans-isomer \u2014 the antiestrogenic half. Pure ER antagonism at the hypothalamus and pituitary. No estrogenic counterweight fighting against it. No 30-day zuclomiphene half-life slowly building up in the background and muddying your results.<\/p>\n<p>For researchers studying the HPG axis, gonadotropin regulation, or estrogen receptor pharmacology, that\u2019s not a minor upgrade. It\u2019s a different compound entirely. Here\u2019s what the data shows and why it matters.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Chemical_Identity_and_Classification\"><\/span><span class=\"ez-toc-section\" id=\"Chemical_Identity_and_Classification\"><\/span>Chemical Identity and Classification<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Enclomiphene is the (E)-geometric isomer of clomiphene \u2014 trans configuration around the central double bond. Usually studied and sold as the citrate salt.<\/p>\n<ul>\n<li><strong>Generic Names:<\/strong> Enclomiphene (USAN), enclomifene (INN)<\/li>\n<li><strong>Molecular Formula (free base):<\/strong> C<sub>26<\/sub>H<sub>28<\/sub>ClNO<\/li>\n<li><strong>Molecular Weight (free base):<\/strong> 405.96 g\/mol<\/li>\n<li><strong>Molecular Formula (citrate salt):<\/strong> C<sub>32<\/sub>H<sub>36<\/sub>ClNO<sub>8<\/sub><\/li>\n<li><strong>Molecular Weight (citrate salt):<\/strong> 598.08 g\/mol<\/li>\n<li><strong>CAS Number (citrate):<\/strong> 7599-79-3<\/li>\n<li><strong>UNII:<\/strong> J303A6U9Y6<\/li>\n<li><strong>ChEMBL ID:<\/strong> CHEMBL1200667<\/li>\n<li><strong>Classification:<\/strong> Nonsteroidal SERM, triphenylethylene derivative<\/li>\n<li><strong>Stereochemistry:<\/strong> (E)-isomer \u2014 trans configuration<\/li>\n<\/ul>\n<p>That (E) vs. (Z) geometry isn\u2019t just a labeling detail. It determines which receptors the molecule activates vs. blocks. Different shape, different pharmacology. Completely.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"From_Clomiphene_to_Enclomiphene_The_Development_Story\"><\/span><span class=\"ez-toc-section\" id=\"From_Clomiphene_to_Enclomiphene_The_Development_Story\"><\/span>From Clomiphene to Enclomiphene: The Development Story<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3>The Clomiphene Problem<\/h3>\n<p><a href=\"https:\/\/lotilabs.com\/product\/clomiphene\/\">Clomiphene citrate<\/a> \u2014 under its branded names \u2014 is roughly 62% enclomiphene and 38% zuclomiphene. First synthesized in the late 1950s. FDA-approved in 1967. Decades of use in reproductive endocrinology research. But here\u2019s the issue: those two isomers do opposite things. Enclomiphene blocks estrogen receptors and pushes gonadotropin release up. Zuclomiphene activates estrogen receptors and pushes it down. You\u2019re running both programs at once. Try designing a clean concentration-response study around that.<\/p>\n<h3>Androxal: Isolating the Useful Half<\/h3>\n<p>Repros Therapeutics thought the answer was obvious \u2014 just use the trans-isomer by itself. They developed enclomiphene as Androxal\u00ae (later EnCyzix). The pitch: pure antiestrogenic HPG axis activation without zuclomiphene fighting against you the whole time.<\/p>\n<p>The regulatory path didn\u2019t go smoothly. FDA sent a Complete Response Letter in 2015 wanting more data. In January 2018, the EMA\u2019s CHMP recommended against marketing authorization. As of today, enclomiphene has zero regulatory approvals anywhere. It\u2019s still an investigational compound \u2014 which, for research purposes, doesn\u2019t diminish its utility as a pharmacological tool at all.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_How_Enclomiphene_Activates_the_HPG_Axis\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_How_Enclomiphene_Activates_the_HPG_Axis\"><\/span>Mechanism of Action: How Enclomiphene Activates the HPG Axis<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The mechanism is elegant and well-understood. It\u2019s textbook SERM pharmacology, but applied specifically to the hypothalamic-pituitary feedback loop.<\/p>\n<h3>Normal Feedback: What\u2019s Happening Baseline<\/h3>\n<p>Estradiol circulates in blood. Hits ER\u03b1 receptors in the hypothalamus. Hypothalamus dials back GnRH pulses. With less GnRH reaching the pituitary, LH and FSH secretion drops. Lower LH means lower gonadal stimulation. Lower testosterone production. That\u2019s negative feedback \u2014 the system keeping itself in check.<\/p>\n<h3>What Enclomiphene Does to That Loop<\/h3>\n<p>It parks on estrogen receptors in the hypothalamus and pituitary. Sits there. Blocks estradiol from binding. Now the brain can\u2019t \u201csee\u201d the estrogen that\u2019s actually circulating. As far as the hypothalamic-pituitary unit is concerned, estrogen is low \u2014 even when it\u2019s not.<\/p>\n<p>Response? GnRH pulses speed up and get bigger. LH and FSH pour out of the pituitary. Gonads get hammered with stimulation.<\/p>\n<p>Actually, it\u2019s more active than usual. You\u2019re not replacing the system. You\u2019re tricking it into working harder.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Enclomiphene_vs_Zuclomiphene_Night_and_Day\"><\/span><span class=\"ez-toc-section\" id=\"Enclomiphene_vs_Zuclomiphene_Night_and_Day\"><\/span>Enclomiphene vs. Zuclomiphene: Night and Day<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This comparison isn\u2019t academic \u2014 it\u2019s the entire reason enclomiphene exists as a separate compound.<\/p>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Enclomiphene (Trans\/E)<\/th>\n<th>Zuclomiphene (Cis\/Z)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>ER Activity<\/strong><\/td>\n<td>Antiestrogenic (blocks ERs)<\/td>\n<td>Estrogenic (activates ERs)<\/td>\n<\/tr>\n<tr>\n<td><strong>HPG Axis Effect<\/strong><\/td>\n\n<td>Antigonadotropic \u2014 suppresses LH\/FSH<\/td>\n<\/tr>\n<tr>\n<td><strong>Half-Life<\/strong><\/td>\n<td>~10 hours<\/td>\n<td>~30 days<\/td>\n<\/tr>\n<tr>\n<td><strong>Tissue Selectivity<\/strong><\/td>\n<td>ER antagonism in hypothalamus\/pituitary<\/td>\n\n<\/tr>\n<tr>\n\n<td>Decreases<\/td>\n<\/tr>\n<tr>\n<td><strong>Accumulation<\/strong><\/td>\n<td>Minimal \u2014 clears in hours<\/td>\n<td>Massive \u2014 half-life is a month<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Look at those half-lives. Ten hours vs. thirty days. That\u2019s not a rounding error \u2014 it\u2019s a 72-fold difference. Week after week, the estrogenic counterweight grows heavier. That pharmacokinetic mismatch is a nightmare for research design.<\/p>\n<p>With enclomiphene alone? Predictable steady-state. Clean washout in a day or two. You know what\u2019s in the system and when it leaves. For anyone designing controlled endocrine studies, that difference is worth the price of admission by itself.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Research_Findings\"><\/span><span class=\"ez-toc-section\" id=\"Research_Findings\"><\/span>Research Findings<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3>HPG Axis Activation<\/h3>\n<p>Enclomiphene drives LH and FSH up. Consistently. Across models. The gonadotropin bump matches what you\u2019d predict from its ER antagonist mechanism \u2014 block estrogen feedback, gonadotropins rise. That last part is key. Enclomiphene does the opposite.<\/p>\n<h3>Testosterone Dynamics<\/h3>\n<p>What doesn\u2019t go up disproportionately: DHT. Researchers interpret this to mean enclomiphene normalizes production through physiological pathways rather than brute-forcing supraphysiological levels. The axis self-regulates. Feedback loops stay operational.<\/p>\n<h3>Versus Exogenous Testosterone<\/h3>\n<p>The comparison is stark. Completely different mechanistic route. Researchers studying HPG axis physiology need to understand that distinction because the downstream biology diverges enormously.<\/p>\n<h3>Metabolic Parameters<\/h3>\n<p>Early data. Not well-characterized yet. But the relationship between ER modulation, gonadotropin dynamics, and metabolic endpoints is an open question that multiple labs are pursuing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Enclomiphene_vs_Racemic_Clomiphene_Practical_Research_Considerations\"><\/span><span class=\"ez-toc-section\" id=\"Enclomiphene_vs_Racemic_Clomiphene_Practical_Research_Considerations\"><\/span>Enclomiphene vs. Racemic Clomiphene: Practical Research Considerations<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Which one do you use? Depends on what you\u2019re studying.<\/p>\n<p><strong>Pick enclomiphene if<\/strong> you want clean pharmacology. One mechanism. Predictable kinetics. No zuclomiphene accumulation muddying concentration-response curves. Ideal for studying pure ER antagonism effects on gonadotropin output.<\/p>\n<p><strong>Pick racemic clomiphene if<\/strong> your study specifically needs to model the interplay between ER agonism and antagonism \u2014 because that mixed pharmacology is the reality of how the racemic drug behaves in vivo.<\/p>\n<p>Loti Labs carries both: <a href=\"https:\/\/lotilabs.com\/product\/enclomiphene-25mg-ml\/\">Enclomiphene 25mg\/ml ($49.99)<\/a> and <a href=\"https:\/\/lotilabs.com\/product\/clomiphene\/\">Clomiphene 40mg\/ml ($39.99)<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Where_Enclomiphene_Fits_Among_SERMs\"><\/span><span class=\"ez-toc-section\" id=\"Where_Enclomiphene_Fits_Among_SERMs\"><\/span>Where Enclomiphene Fits Among SERMs<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Enclomiphene is a triphenylethylene SERM \u2014 same chemical family as tamoxifen and toremifene. All three modulate estrogen receptors. All three have different tissue selectivity profiles and metabolic pathways.<\/p>\n<ul>\n<li><strong>Tamoxifen<\/strong> generates active metabolites \u2014 4-hydroxytamoxifen, endoxifen \u2014 each with their own receptor binding profiles. Mechanistic studies get complicated fast. More background in the Loti Labs <a href=\"https:\/\/lotilabs.com\/resources\/what-is-tamoxifen-citrate\/\">tamoxifen review<\/a><\/li>\n<li><strong>Enclomiphene<\/strong> has simpler metabolism, shorter half-life, and a more straightforward pharmacological profile. Better suited for acute and sub-chronic protocols where you want clear cause-and-effect<\/li>\n<li><strong>Toremifene<\/strong> swaps in a different chlorine substitution pattern.<\/li>\n<\/ul>\n<p>If your research specifically targets HPG axis modulation through pituitary ER antagonism, enclomiphene\u2019s profile makes it the most practical choice of the three. Related work on aromatase inhibition and estrogen management is covered in the <a href=\"https:\/\/lotilabs.com\/resources\/what-is-anastrozole\/\">anastrozole guide<\/a> and <a href=\"https:\/\/lotilabs.com\/resources\/estrogen-inhibitors-in-breast-cancer-treatment\/\">estrogen inhibitor overview<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Safety_Profile_and_Research_Considerations\"><\/span><span class=\"ez-toc-section\" id=\"Safety_Profile_and_Research_Considerations\"><\/span>Safety Profile and Research Considerations<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>SERM territory, SERM considerations:<\/p>\n<ul>\n<li><strong>ER modulation effects:<\/strong> Theoretical thromboembolic risk \u2014 standard concern for any compound that touches estrogen receptors. Factor it into protocol design<\/li>\n<li><strong>No HPG suppression:<\/strong> Unlike exogenous androgens, enclomiphene doesn\u2019t shut down the axis. No spermatogenesis loss. No testicular atrophy. That\u2019s a fundamental difference from androgen replacement<\/li>\n\n<li><strong>Visual disturbances:<\/strong> Racemic clomiphene has this in its adverse event profile. Whether it\u2019s enclomiphene, zuclomiphene, or both causing it remains unclear<\/li>\n<\/ul>\n<p><em>Enclomiphene is investigational. No FDA approval. No marketing authorization from any regulatory body. Interpret all data in the context of study design.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span>Regulatory Status<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No approvals. Anywhere. The FDA sent a Complete Response Letter in 2015. The EMA CHMP recommended refusal in January 2018. Those decisions related to specific development program requirements \u2014 not safety signals that would affect legitimate research use. Racemic clomiphene citrate (the parent compound) does hold FDA approval. Enclomiphene isn\u2019t a controlled substance and is legally available for laboratory research in the U.S.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Research_Compound_Availability\"><\/span><span class=\"ez-toc-section\" id=\"Research_Compound_Availability\"><\/span>Research Compound Availability<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Loti Labs offers:<\/p>\n<ul>\n<li><strong><a href=\"https:\/\/lotilabs.com\/product\/enclomiphene-25mg-ml\/\">Enclomiphene 25mg\/ml \u2014 $49.99<\/a>:<\/strong> Research-grade liquid, enclomiphene citrate<\/li>\n<li><strong><a href=\"https:\/\/lotilabs.com\/product\/clomiphene\/\">Clomiphene 40mg\/ml \u2014 $39.99<\/a>:<\/strong> Racemic clomiphene citrate for comparative work<\/li>\n<\/ul>\n<p>Third-party purity tested. Details on quality standards <a href=\"https:\/\/lotilabs.com\/resources\/ensure-purity-best-3rd-party-tested-peptides-for-research\/\">here<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Enclomiphene is clomiphene without the contradictions. One isomer. One mechanism. Predictable kinetics with a 10-hour half-life instead of zuclomiphene\u2019s month-long accumulation. For HPG axis researchers, that clarity is the whole point.<\/p>\n<p>Whether you\u2019re studying ER antagonism, gonadotropin dynamics, or the mechanistic gap between SERM-mediated stimulation and direct androgen replacement, <a href=\"https:\/\/lotilabs.com\/product\/enclomiphene-25mg-ml\/\">enclomiphene<\/a> gives you a cleaner tool to work with than the racemic mixture ever could.<\/p>\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Kaminetsky J, et al. <em>BMC Endocrine Disorders<\/em>. 2013;13:45. doi:10.1186\/1472-6823-13-45<\/li>\n<li>Wiehle RD, et al. <em>Fertility and Sterility<\/em>. 2014;102(3):720-727. doi:10.1016\/j.fertnstert.2014.06.004 (PMID: 25044080)<\/li>\n<li>Kim ED, et al. <em>BJU International<\/em>. 2016;117(4):677-685. doi:10.1111\/bju.13313<\/li>\n<li>Rodriguez KM, et al. Enclomiphene citrate for the treatment of secondary male hypogonadism. <em>Expert Opinion on Pharmacotherapy<\/em>. 2016;17(11):1561-1567. doi:10.1080\/14656566.2016.1204295 (PMID: 27337642)<\/li>\n<li>Fontenot GK, et al. Zuclomiphene is estrogenic and antigonadotropic in male rats whereas enclomiphene is anti-estrogenic and progonadotropic. <em>Biology of Reproduction<\/em>. 2016;95(6):131. doi:10.1095\/biolreprod.116.142935<\/li>\n<li>European Medicines Agency. Refusal of the marketing authorisation for enclomifene (EnCyzix). EMA\/30155\/2018. January 2018.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Research guide on enclomiphene citrate, the trans-isomer of clomiphene that selectively blocks estrogen receptors. <\/p>\n","protected":false},"author":1,"featured_media":1382,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1372","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1372"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1372\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1382"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}